SGMO Surges as FDA Accepts Gene Therapy Submission
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 15 2025
0mins
Source: SeekingAlpha
Shares of Sangamo Therapeutics (SGMO.O) saw a notable uptick today, crossing above its 5-day simple moving average (SMA) amid positive market sentiment. This movement follows the recent announcement that the FDA has accepted Sangamo's request for a rolling submission of its Biologics License Application for isaralgagene civaparvovec, a promising gene therapy aimed at treating Fabry disease.
The stock's technical breakout signals increased investor confidence, particularly in light of the Phase 1/2 STAAR study results, which demonstrated the therapy's potential to offer a one-time, durable treatment with significant multi-organ benefits, exceeding current care standards. Additionally, the therapy has garnered multiple regulatory designations, including Orphan Drug and Fast Track status from the FDA, further enhancing its market appeal.
Sangamo plans to initiate the rolling submission of the BLA under the accelerated approval pathway in the fourth quarter of 2025, which could position the company favorably within the competitive landscape of gene therapies. Investors are closely monitoring these developments as they could significantly influence SGMO's stock trajectory in the coming months.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SGMO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SGMO
Wall Street analysts forecast SGMO stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 0.178
Low
1.00
Averages
3.75
High
10.00
Current: 0.178
Low
1.00
Averages
3.75
High
10.00
About SGMO
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sangamo Therapeutics Q1 2026 Earnings Call Insights
- BLA Submission Progress: Sangamo is advancing the rolling submission of the BLA for ST-920 in Fabry disease, with expectations to complete it as early as this summer, contingent on securing adequate funding, which could open significant market access opportunities for the company.
- Stock Trading Change: Sangamo's common stock has transitioned to trading on the OTCQB market due to noncompliance with NASDAQ's minimum bid requirements, and the company plans to appeal the delisting determination in June, which may impact investor confidence.
- Funding Needs Focus: Management emphasized actively seeking additional capital and evaluating all strategic options to maximize asset value, highlighting the company's dependency on financing in the current market environment.
- FDA Regulatory Dynamics: The FDA confirmed that no additional confirmatory study is required for ST-920, allowing for the submission of 104-week data to support traditional approval, providing greater flexibility and confidence in regulatory approval processes for the company.
See More
Sangamo Therapeutics to Announce Q1 Earnings on May 14
- Earnings Announcement Date: Sangamo Therapeutics (SGMO) is set to release its Q1 2023 earnings on May 14 after market close, with consensus EPS estimated at $0.04 and revenue projected at $33.73 million, reflecting a substantial 427% year-over-year increase.
- Performance Expectations: Over the past year, SGMO has only beaten EPS and revenue estimates 25% of the time, indicating challenges in profitability and revenue growth that could impact investor confidence moving forward.
- Estimate Revision Trends: In the last three months, EPS estimates saw no upward revisions and one downward revision, while revenue estimates experienced one upward and one downward revision, suggesting instability in market expectations regarding the company's future performance.
- Market Response: Despite facing performance pressures, Sangamo is advancing its neurology pipeline and targeting a Fabry BLA submission, demonstrating ongoing commitment to R&D efforts that may lay the groundwork for future growth.
See More
Sangamo Therapeutics Schedules Q1 2026 Financial Results Release
- Financial Results Announcement: Sangamo Therapeutics is set to release its Q1 2026 financial results after market close on May 14, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will hold a conference call at 4:30 PM Eastern on the same day to discuss financial results and business updates, which is expected to attract significant attention from investors and analysts.
- Participation Registration Recommended: Participants are advised to register and join the call 10 minutes early, with options for both dial-in and dial-out connections provided to enhance engagement and interactivity during the call.
- Replay Availability: A replay of the financial results will be accessible on the company's website under the 'Investors and Media' section post-conference, further improving information accessibility and transparency for stakeholders.
See More
PEPG, SGMO, and PHR Shares Decline Amid Disappointing Results
- PEPG Trial Disappointment: PepGen's Phase 2 Freedom 2 study results showed no significant improvements in walking speed or hand strength at the starting dose of 5 mg/kg, leading to a 45% plunge in premarket trading, reflecting investor disappointment in the therapy's efficacy.
- SGMO Earnings Miss: Sangamo Therapeutics reported a Q4 loss per share of $0.11, wider than the expected $0.05 loss, despite revenue rising to $14.23 million, indicating pressure on the company's funding outlook that may impact future operations.
- PHR Revenue Outlook Cut: Phreesia lowered its fiscal 2027 revenue outlook to $510 million to $520 million, below analyst expectations of $552.1 million, resulting in a 27% drop in share price and prompting downgrades from multiple brokerages.
- Market Sentiment Fluctuates: While retail sentiment for PEPG, SGMO, and PHR on Stocktwits was 'extremely bullish', the disappointing performance and unclear outlook have severely undermined investor confidence, reflecting a cautious attitude towards biotech stocks.
See More
Sangamo Therapeutics Secures Over $130 Million in Funding and FDA Fast Track Designation
- Funding Progress: Since the beginning of 2025, Sangamo Therapeutics has raised over $130 million through non-dilutive license fees, milestone payments, and equity financing, providing essential funding for ongoing research and enhancing its competitive position in the market.
- Clinical Advancement: The company has initiated a rolling submission of a Biologics License Agreement (BLA) for ST-920 to the FDA, having completed both non-clinical and clinical modules, marking its first wholly-owned BLA submission that could expedite the FDA approval process.
- Fast Track Designation: Sangamo received Fast Track designation from the FDA for SC503, an investigational treatment for intractable pain due to small fiber neuropathy, highlighting its potential to address significant unmet medical needs in this area.
- Clinical Trial Activation: Six clinical sites have been activated for the Phase I/II STAN study in chronic neuropathic pain, demonstrating the company's proactive efforts in advancing clinical research to provide new treatment options for patients.
See More
Sangamo Therapeutics Q4 2025 Earnings Call Insights
- Significant Pipeline Progress: Sangamo made notable advancements in 2025, particularly with positive results from the registrational STAAR study for Fabry disease, where the eGFR slope at 52 weeks was promising, and the FDA confirmed this may serve as the primary basis for accelerated approval, indicating the company's ability to achieve positive outcomes amid regulatory complexities.
- BLA Submission Progress: The company is advancing its first wholly owned BLA's rolling submission, with expectations to complete it as early as this summer, despite facing challenges related to limited cash resources, which will lay the groundwork for future commercialization efforts.
- Successful Fundraising: Since the beginning of 2025, Sangamo has raised over $130 million through nondilutive license fees, milestone payments, and equity financing, providing essential financial support for ongoing R&D and market expansion initiatives.
- Neurology Pipeline Expansion: The company has activated six clinical sites in the STAND study and entered into a third neurology capsid license agreement with Eli Lilly to deliver genomic medicines for up to five CNS disease targets, demonstrating its strategic positioning in the neurology sector.
See More
Sangamo Therapeutics Q1 2026 Earnings Call Insights
- BLA Submission Progress: Sangamo is advancing the rolling submission of the BLA for ST-920 in Fabry disease, with expectations to complete it as early as this summer, contingent on securing adequate funding, which could open significant market access opportunities for the company.
- Stock Trading Change: Sangamo's common stock has transitioned to trading on the OTCQB market due to noncompliance with NASDAQ's minimum bid requirements, and the company plans to appeal the delisting determination in June, which may impact investor confidence.
- Funding Needs Focus: Management emphasized actively seeking additional capital and evaluating all strategic options to maximize asset value, highlighting the company's dependency on financing in the current market environment.
- FDA Regulatory Dynamics: The FDA confirmed that no additional confirmatory study is required for ST-920, allowing for the submission of 104-week data to support traditional approval, providing greater flexibility and confidence in regulatory approval processes for the company.
See More
Sangamo Therapeutics to Announce Q1 Earnings on May 14
- Earnings Announcement Date: Sangamo Therapeutics (SGMO) is set to release its Q1 2023 earnings on May 14 after market close, with consensus EPS estimated at $0.04 and revenue projected at $33.73 million, reflecting a substantial 427% year-over-year increase.
- Performance Expectations: Over the past year, SGMO has only beaten EPS and revenue estimates 25% of the time, indicating challenges in profitability and revenue growth that could impact investor confidence moving forward.
- Estimate Revision Trends: In the last three months, EPS estimates saw no upward revisions and one downward revision, while revenue estimates experienced one upward and one downward revision, suggesting instability in market expectations regarding the company's future performance.
- Market Response: Despite facing performance pressures, Sangamo is advancing its neurology pipeline and targeting a Fabry BLA submission, demonstrating ongoing commitment to R&D efforts that may lay the groundwork for future growth.
See More
Sangamo Therapeutics Schedules Q1 2026 Financial Results Release
- Financial Results Announcement: Sangamo Therapeutics is set to release its Q1 2026 financial results after market close on May 14, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will hold a conference call at 4:30 PM Eastern on the same day to discuss financial results and business updates, which is expected to attract significant attention from investors and analysts.
- Participation Registration Recommended: Participants are advised to register and join the call 10 minutes early, with options for both dial-in and dial-out connections provided to enhance engagement and interactivity during the call.
- Replay Availability: A replay of the financial results will be accessible on the company's website under the 'Investors and Media' section post-conference, further improving information accessibility and transparency for stakeholders.
See More
PEPG, SGMO, and PHR Shares Decline Amid Disappointing Results
- PEPG Trial Disappointment: PepGen's Phase 2 Freedom 2 study results showed no significant improvements in walking speed or hand strength at the starting dose of 5 mg/kg, leading to a 45% plunge in premarket trading, reflecting investor disappointment in the therapy's efficacy.
- SGMO Earnings Miss: Sangamo Therapeutics reported a Q4 loss per share of $0.11, wider than the expected $0.05 loss, despite revenue rising to $14.23 million, indicating pressure on the company's funding outlook that may impact future operations.
- PHR Revenue Outlook Cut: Phreesia lowered its fiscal 2027 revenue outlook to $510 million to $520 million, below analyst expectations of $552.1 million, resulting in a 27% drop in share price and prompting downgrades from multiple brokerages.
- Market Sentiment Fluctuates: While retail sentiment for PEPG, SGMO, and PHR on Stocktwits was 'extremely bullish', the disappointing performance and unclear outlook have severely undermined investor confidence, reflecting a cautious attitude towards biotech stocks.
See More
Sangamo Therapeutics Secures Over $130 Million in Funding and FDA Fast Track Designation
- Funding Progress: Since the beginning of 2025, Sangamo Therapeutics has raised over $130 million through non-dilutive license fees, milestone payments, and equity financing, providing essential funding for ongoing research and enhancing its competitive position in the market.
- Clinical Advancement: The company has initiated a rolling submission of a Biologics License Agreement (BLA) for ST-920 to the FDA, having completed both non-clinical and clinical modules, marking its first wholly-owned BLA submission that could expedite the FDA approval process.
- Fast Track Designation: Sangamo received Fast Track designation from the FDA for SC503, an investigational treatment for intractable pain due to small fiber neuropathy, highlighting its potential to address significant unmet medical needs in this area.
- Clinical Trial Activation: Six clinical sites have been activated for the Phase I/II STAN study in chronic neuropathic pain, demonstrating the company's proactive efforts in advancing clinical research to provide new treatment options for patients.
See More
Sangamo Therapeutics Q4 2025 Earnings Call Insights
- Significant Pipeline Progress: Sangamo made notable advancements in 2025, particularly with positive results from the registrational STAAR study for Fabry disease, where the eGFR slope at 52 weeks was promising, and the FDA confirmed this may serve as the primary basis for accelerated approval, indicating the company's ability to achieve positive outcomes amid regulatory complexities.
- BLA Submission Progress: The company is advancing its first wholly owned BLA's rolling submission, with expectations to complete it as early as this summer, despite facing challenges related to limited cash resources, which will lay the groundwork for future commercialization efforts.
- Successful Fundraising: Since the beginning of 2025, Sangamo has raised over $130 million through nondilutive license fees, milestone payments, and equity financing, providing essential financial support for ongoing R&D and market expansion initiatives.
- Neurology Pipeline Expansion: The company has activated six clinical sites in the STAND study and entered into a third neurology capsid license agreement with Eli Lilly to deliver genomic medicines for up to five CNS disease targets, demonstrating its strategic positioning in the neurology sector.
See More
